Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. - Wikidata - awgldk - TriplyDB

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

http://www.wikidata.org/entity/Q34629100

about

Recent progress in pancreatic cancer Systemic Chemotherapy in Advanced Pancreatic Cancer Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials Advances in systemic therapy for advanced pancreatobiliary malignancies Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Pancreatic cancer: New hopes after first line treatment Advances in chemotherapy for pancreatic cancer Pancreatic cancer: yesterday, today and tomorrow.DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study Ductal pancreatic adenocarcinoma.Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.Current and future systemic treatment options in metastatic pancreatic cancer.First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract.Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.S-1 in the treatment of pancreatic cancer.Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies.Viral vector-based therapeutic cancer vaccines A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.Clinical evaluation of TRICOM vector therapeutic cancer vaccines Pancreatic Cancer: Progress in Systemic Therapy.Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?

P2860

Q24626346-46106DB0-9DB6-434B-BFB0-82753060B1B8 Q26750440-8BBBA5F4-4A61-4DF0-BA0C-8D6A132EF741 Q26767041-3FBB4F39-6066-4D93-BAEE-C91BB6C08C75 Q26781538-5ADCA3AA-4231-4F7E-8B74-03A6CA7B1F4F Q26822703-E21819FF-E3A1-4093-9AAC-E753C2554E29 Q26830913-F9974CF4-2669-475F-A4FC-14CE744B68C2 Q28067055-74F4434D-0516-49CF-A913-BA75D9216DB5 Q28085711-CD1BB14A-20BF-42A1-8A18-9E4B2A69B44A Q30250026-23582DD3-5E7C-4DE1-A432-F9E1E91C7D18 Q30315797-428EAD9A-FBA0-41C9-AEE1-A4F1C4F7CECA Q30978290-C8A2CA67-57BD-4283-8B58-BD70A3E76E4E Q33415850-EFA42FBE-FDC1-4D2F-AAD7-CC34E5246FB3 Q33425869-5474534B-2FB9-459D-A3BD-4E94E4B2C07F Q33426575-AA31CBBC-FAA8-491A-B2B0-2FECE30EE8BC Q33428382-72671A8F-5FD9-4728-BAE6-5E54DE3ACFA6 Q33443909-3EADDC38-716F-4FE5-895C-F7E2E9FF7A53 Q33606097-0878C483-0E3A-41F1-ACDA-F276E62FF723 Q33672571-CB08A1F5-8D64-4ADC-B15B-D77345B813FA Q33751227-9B46BA63-60F9-43CD-8209-C215BC303BB7 Q33823212-94B546C1-A301-4FA2-89F6-98ACE9F85AAE Q33832655-4D5367D8-794D-4CF0-9067-34803C6F5F9C Q33913549-89DF792B-A3FC-4F28-BCE7-BFD2286B91BF Q33948033-C129BC8F-1416-4737-8271-F521B1A0F2AE Q34008520-331E9652-5374-4346-9840-FB1001975F7C Q34301038-C1157EB9-7C7D-46D6-942C-4C578BDEF8A9 Q34404088-9AFDE839-1699-4AA3-847A-0EFD1A88A8DF Q34431614-FB33C505-1945-468A-B94E-22F07F8DB2FB Q34467156-16E7C1F3-235A-4315-AF0E-E7013DD4F00D Q35136815-4798E12A-7111-4452-85AE-36815B9707CC Q35515080-B7228266-9907-441E-ACF6-59C1180134D4 Q35703105-1CF95197-EC13-4E9D-BD5F-0C337D5627AC Q35703129-091D748F-05C9-41B3-897F-29B0A7E82891 Q35828693-D7819AEC-B73D-409C-80D4-8EE97A024838 Q35890548-2413CE05-5B52-434E-9824-E5C98565A57F Q36062637-D18B8531-B59A-4EF9-9CAF-293A827DA450 Q36093374-10A092CC-8F32-460F-99B6-E48014E789D4 Q36099965-2B5FF020-2605-468D-A10D-DEEDDC5C257B Q36344551-8EC91ED5-2D23-4F83-9410-888C45BF2AAA Q36595053-E6C7498C-C9D6-4FE8-BF39-6581BA1C2597 Q36682682-BA20FBD1-0D4C-4503-80F6-158FAE1D1F7F

P2860

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

http://www.wikidata.org/entity/Q34629100

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Best supportive care (BSC) ver ...... the German CONKO-study group.

@ast

Best supportive care (BSC) ver ...... the German CONKO-study group.

@en

Best supportive care (BSC) ver ...... the German CONKO-study group.

@nl

type

label

Best supportive care (BSC) ver ...... the German CONKO-study group.

@ast

Best supportive care (BSC) ver ...... the German CONKO-study group.

@en

Best supportive care (BSC) ver ...... the German CONKO-study group.

@nl

prefLabel

Best supportive care (BSC) ver ...... the German CONKO-study group.

@ast

Best supportive care (BSC) ver ...... the German CONKO-study group.

@en

Best supportive care (BSC) ver ...... the German CONKO-study group.

@nl

P1433

Q34629100-1191870E-5973-4CF5-B449-C6713E32344C

P1476

Q34629100-E0231A28-F279-437D-9914-1A7A1C6A0865

P2093

Q34629100-1995E5AC-6163-44BB-BB6D-5DBB4DBE7813

Q34629100-1B326F53-EF3F-4275-9A1B-5832FD48395A

Q34629100-3B6CEEF3-9A3F-44AA-855B-78F57098BF2C

Q34629100-44B7A8D3-C202-4DA6-8CCD-49DC9B350A69

Q34629100-4651965B-660D-4E9A-A16D-9810DDDF45B7

Q34629100-6C91C0F7-6BE1-432C-8C76-6BBCB7B9ADF3

Q34629100-77B89836-CA96-422C-B6E5-26DFC9072655

Q34629100-F8524DCE-FEE5-4ABF-A1F6-B4D283BDD133

P304

Q34629100-3E217E99-1E16-4D68-8E52-1C7D7D8F8F02

P31

Q34629100-86649043-E5F5-461A-A99F-6D2A1EF8BD1F

P356

Q34629100-B7C60F82-2A88-4402-90B6-0941A6C5F380

P433

Q34629100-D0F328A7-67BA-4B60-A05E-9C22C3622650

P478

Q34629100-97B99A42-769F-4763-A074-995EC1331732

P577

Q34629100-4E8C2791-3A85-4F02-BC25-FC064486AB95

P5875

Q34629100-41D55E86-08EB-44EE-A1E8-3F94EA389A4D

P698

Q34629100-728C50D4-9FB3-456E-8FC1-3CA1336D43F5

P921

Q34629100-9C1E65EE-79DF-4379-A9AB-71403960949B

P356

J.EJCA.2011.04.011

P1433

European Journal of Cancer

P1476

Best supportive care (BSC) ver ...... the German CONKO-study group.

@en

P2093

Bernd Dörken

http://www.w3.org/2001/XMLSchema#string

Hanno Riess

http://www.w3.org/2001/XMLSchema#string

Helmut Oettle

http://www.w3.org/2001/XMLSchema#string

Ingo Schwaner

http://www.w3.org/2001/XMLSchema#string

Jens Stieler

http://www.w3.org/2001/XMLSchema#string

Jörg Seraphin

http://www.w3.org/2001/XMLSchema#string

Mathias Adler

http://www.w3.org/2001/XMLSchema#string

Uwe Pelzer

http://www.w3.org/2001/XMLSchema#string

P304

1676-1681

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJCA.2011.04.011

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51120286

http://www.w3.org/2001/XMLSchema#string

P698

21565490

http://www.w3.org/2001/XMLSchema#string

P921